News

One global clinical trial testing astegolimab for moderate to severe COPD hit its main goal, but another did not, Genentech ...
Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.
Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...
Clinical Trials Arena on MSN6d
Mixed results from Roche’s mAb in COPD
Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...
Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...
Astegolimab’s data readout follows mixed results for an IL-33-blocking antibody from Regeneron Pharmaceuticals. In May, Regeneron reported this drug, itepekimab, met the main goal of one Phase 3 ...
Between baseline and week 16, patients in the astegolimab group experienced an adjusted mean percent change of –51.47% (95% CI, –68.75 to –34.19) in their Eczema Area and Severity Index ...
Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...
The astegolimab COPD clinical program includes the phase 2b ALIENTO (ClinicalTrials.gov Identifier: NCT05037929) and the phase 3 ARNASA (ClinicalTrials.gov Identifier: NCT05595642) trials.